The New Economics of Gene Therapy
Cell and gene therapies are no longer reserved only for ultra-rare diseases. In many therapeutic areas (TAs), advances in viral vector delivery, gene editing technologies, and cell-based medicine are enabling interventions that target disease at its biological source, often through a single administration rather than lifelong treatment. These developments should be unequivocally positive for patients. […]
The Evolving Payer Landscape for Early Detection Tests
In many therapeutic areas, especially oncology, physicians have been using early screening tests for decades. Designed to identify the early signs of a disease or condition before any noticeable symptoms develop, early detection tests support timely medical intervention. In the U.S. alone, early cancer screenings have been credited with preventing 4.75 million deaths (and counting) […]
Winning Payer Support for Rapid NGS Biomarker Testing in Oncology
Biomarker testing is a cornerstone of modern oncology, transforming how clinicians diagnose, stratify, and treat cancer. By identifying particular genetic, molecular, or protein characteristics in a patient’s tumor or blood sample, biomarker tests provide invaluable insights into disease behavior and a patient’s potential response to various therapies. In recent years, advances in next-generation sequencing (NGS) […]
Market Access in 2026: Predictions on DTC Programs, Biosimilars and GLP-1s
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read on for key insights into the year ahead (and don’t miss the first post in this two-part series.) 1. Patients are increasingly gravitating to direct-to-consumer platforms. What effects do you think these […]
Competitive ATTR Dynamics: Key Takeaways for Rare-Disease Commercialization
Transthyretin amyloidosis (ATTR) has rapidly shifted from a rarely recognized, fatal condition into one of the most closely watched rare-disease markets in biopharma. With multiple therapeutic entrants, distinct scientific platforms, and increasingly sophisticated payer strategies, ATTR now serves as a template for how innovation, diagnosis expansion, pricing, and access come together to shape a complex […]
New Treatments, Diagnostic Tests and Access Barriers in NSCLC
The oncology market is growing rapidly, driven by advancements in diagnostic technology, new biomarker testing, and a wealth of targeted therapies. The non-small cell lung cancer (NSCLC) space is especially crowded, which should be good news for the 226,000 patients diagnosed with this disease each year. Despite the new developments in NSCLC treatment, however, many […]
A New Era in HAE: How Market Entrants Are Reshaping Rare Disease Treatment
As medicine evolves, even smaller therapeutic areas are impacted by scientific breakthroughs and novel technologies, leading to an eruption of new therapies. Hereditary angioedema (HAE), a rare genetic disorder affecting 1 in 50,000 people worldwide, is the latest indication to reap the benefits of several new market entrants. Due to a deficiency of the C1 […]
Quantifying Value: Innovative Contracting for High-Cost Drugs
As high-cost specialty treatments become more common, manufacturers are turning to innovative contracting to boost coverage for their products. Many cell and gene therapies, orphan drugs, and oncology therapies are prohibitively expensive, with costs ranging from several hundred thousand to millions of dollars. Warranty-based agreements help mitigate the risk of paying for these therapies, as […]
Mining the Hidden Gems in Unstructured EMR Data
This article was originally published in BioPharma Dive. Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR data is the unsung hero of most queries. Whether a manufacturer is struggling to find a niche patient population, conduct unbiased outcomes research, or generate persuasive […]
How Copay Accumulators and Maximizers Affect Pharma PAPs
In a recent post on specialty carve-out mechanisms, we examined how payers’ use of specialty benefit managers and alternative funding programs can impact manufacturers’ patient assistance programs (PAPs). Today’s post takes a look at another managed care trend: the rise of copay accumulators and maximizers, also known as copay adjustment programs. In 2025, copay accumulator […]